Proactive Investors - Run By Investors For Investors

Mediland Pharm moves to acquire retail and e-commerce business with presence in China

The acquisition will give the company access to China-based retail customers through e-commerce and online platforms as well as a network of retail stores.
Medilands plans to establish an online sales channel to maintain contact with its Chinese tourist customers

Mediland Pharm Ltd (ASX:MPH) has entered into a conditional business sales agreement to acquire Ian’s Health Lounge, a complimentary business with established e-commerce platforms and retail franchise stores in China.

After establishing in Australia in 2012, the business later launched its first online platform in China in 2015 with the aim of promoting quality baby and nutritional products to Chinese retail customers.

The business has successfully created a model of setting up online platforms in China and has grown to incorporate one direct shop in Australia, six franchise shops in China, three WeChat accounts and four e-commerce platforms with operating entities and employees in Australia and China.

Online channel to promote brand

Mediland Pharm managing director Yesh Mudaliar said: “One of our growth strategies is to promote our brand to our customers when they return home.

“We know that an online channel is a great way to keep in contact with our customers providing them with a platform to continue purchasing products from Mediland Pharm.

“Once the business transaction has been finalised, we will be able to quickly inject product range onto the online platform and start promoting Mediland to current customers and work towards promoting our online channel to customers that are visiting our stores from China.”

It is expected the transaction will be completed by the end of June subject to usual and ordinary conditions, including the board being satisfied with the due diligence on the business.

The business’ products target the health and well-being market.

View full MPH profile View Profile

Mediland Pharm Ltd Timeline

Related Articles

cancerous cells
March 08 2019
A series of trials underway at major cancer research hospitals are evaluating the company's flagship cancer drug Ampligen
Scientist at work
May 28 2019
CaPre, a potent form of Omega-3, has been shown to reduce triglycerides, but also lower 'bad cholesterol' levels, and raise 'good' ones
Dyadic Dyadic International founder and CEO Mark Emalfarb
June 05 2019
The biotechnology platform company helps drug makers negotiate the cost curve from discovery to large-scale manufacturing of low-cost enzymes and proteins that can ultimately lower the cost of healthcare

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use